Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study / Kirsten Behnke en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 4 (Agosto)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 4 (Agosto) . - pp. 358-364 Título : Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study Tipo de documento: texto impreso Autores: Kirsten Behnke, Autor ; Jesper Søgaard, Autor ; Stephen Martin, Autor Fecha de publicación: 2023 Artículo en la página: pp. 358-364 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos Tricíclicos, Trastorno depresivo, Mianserin, Mirtazapina, Sertralina, Disfunción sexual fisiológica Resumen: This multinational, randomized, double-blind study was specifically designed to prospectively compare the onset of antidepressant efficacy of mirtazapine orally disintegrating tablets and sertraline at dosages commonly used in clinical practice. A total of 345 patients with major depressive episode (DSM-IV) received mirtazapine (30–45 mg/d) or sertraline (50–150 mg/d) for 8 weeks. Link: ./index.php?lvl=notice_display&id=31010 [artículo] Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study [texto impreso] / Kirsten Behnke, Autor ; Jesper Søgaard, Autor ; Stephen Martin, Autor . - 2023 . - pp. 358-364. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 4 (Agosto) . - pp. 358-364 Palabras clave: Antidepresivos Tricíclicos, Trastorno depresivo, Mianserin, Mirtazapina, Sertralina, Disfunción sexual fisiológica Resumen: This multinational, randomized, double-blind study was specifically designed to prospectively compare the onset of antidepressant efficacy of mirtazapine orally disintegrating tablets and sertraline at dosages commonly used in clinical practice. A total of 345 patients with major depressive episode (DSM-IV) received mirtazapine (30–45 mg/d) or sertraline (50–150 mg/d) for 8 weeks. Link: ./index.php?lvl=notice_display&id=31010

---

1 (1 - 1 / 1)